-
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation.
Carbone IF, Cruz JJ, Sarquis R, Akolekar R, Nicolaides KH.
Hum Reprod 2011;26:1659-64. -
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
Prenat Diagn 2011;31:802-8. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Maternal serum progesterone-induced blocking factor at 11-13 weeks gestation in spontaneous early preterm delivery.
Beta J, Szekeres-Bartho J, Skyfta E, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;29:197-200. -
Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH.
Prenat Diagn 2011;31:33-7. -
Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Obstet Gynecol 2011;117:293-8. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
Prenat Diagn 2011;31:38-45. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
Fetal Diagn Ther 2011;29:301-6. -
Collagen type VI gene expression in the skin of trisomy 21 fetuses.
von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F, Nicolaides KH.
Obstet Gynecol 1998;91:319-23. -
Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse.
von Kaisenberg CS, Krenn V, Ludwig M, Nicolaides KH, Brand-Saberi B.
Anat Embryol 1998;197:105-24. -
Endoscopic laser coagulation in the management of severe twin-to-twin transfusion syndrome.
Ville Y, Hecher K, Gagnon A, Sebire N, Hyett J, Nicolaides K.
BJOG 1998;105:446-53. -
Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation.
Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH.
Ultrasound Obstet Gynecol 1998;11:391-400. -
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH.
Lancet 1998;352:343-6. -
Cerebellar hypoplasia, facial dysmorphism and internal abnormalities: a new recessive syndrome?
Seller MJ, Pal K, Moscoso G, Nicolaides K, Hyett JA.
Clin Dysmorphol 1998;7:41-4.